Eisai presents Phase 3 data: October 25 brings new evidence for Eisai stock

Published on 10/25/2026 at 01:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Three Phase 3 studies anchor Eisai's oncology update at ESMO. The October 25 presentations set a test for Eisai stock before November 9 results.

Oncology evidence and reporting date

Eisai announced three Phase 3 oncology studies for ESMO on October 15, 2026.
The LITESPARK-011 analysis is scheduled for October 25, 2026.
Eisai stock last stood at JPY 5,076.00 on October 23, 2026.
Eisai's next results release is scheduled for November 9, 2026.

Eisai, JP3160400002, Illustration mit AI erstellt.

Eisai (ISIN JP3160400002) announced on October 15, 2026, that it would present results from three Phase 3 oncology studies at the European Society for Medical Oncology Congress. Yahoo Finance reported that the presentations are scheduled for October 23 to October 27, with major renal-cell-carcinoma data due on October 25.

October 25 brings trial data

The most important item is the final analysis of the Phase 3 LITESPARK-011 study, which compares belzutifan plus lenvatinib with cabozantinib in advanced renal cell carcinoma. Eisai also plans a separate LITESPARK-012 presentation covering investigational first-line regimens, while the LEAP-001 study adds biomarker data in endometrial cancer.

The LITESPARK-011 final analysis is listed as presentation 3587O for October 25, 2026. A second presentation, numbered 3595RO, will examine health-related quality of life and treatment efficacy. The schedule gives investors a defined near-term evidence point, but the release does not provide the final results in advance.

What does the pipeline add?

The oncology update broadens the evidence base around LENVIMA, Eisai's multiple receptor tyrosine kinase inhibitor. The company said the LITESPARK-011 data supported the U.S. approval of WELIREG plus LENVIMA for certain previously treated patients with advanced clear-cell renal cell carcinoma, linking the October program to a commercial indication.

The context is a business with a broad pharmaceutical portfolio spanning neurology and oncology. Eisai's first-quarter fiscal 2026 revenue was JPY 234.33 billion and operating income was JPY 24.70 billion, figures reported for the period ended June 30, 2026. These figures are structured financial data and are not used as a forecast.

Three events set the sequence

On August 3, 2026, Eisai held its first-quarter fiscal 2027 earnings call. On September 28, 2026, the U.S. Food and Drug Administration approved the WELIREG and LENVIMA combination for a defined advanced kidney-cancer population. On October 15, 2026, Eisai announced the three-study ESMO program, according to MarketScreener and Yahoo Finance.

Results date sets the next marker

The next scheduled reporting date is November 9, 2026, when Eisai is listed to release second-quarter fiscal 2027 results. The upcoming presentation and the results date create two separate checkpoints for assessing whether oncology development is translating into commercial performance.

Tokyo valuation remains the market reference

Eisai last stood at JPY 5,076.00 on the Tokyo Stock Exchange on October 23, 2026 at 3:30 p.m. JST. Its 52-week range was JPY 3,660.00 to JPY 5,243.00, while market capitalization was JPY 1.4 trillion as of the same market date. The further course of trading is shown by the continuously updated real-time quote of Eisai stock.